Brief: Adhera Therapeutics Signs Letter Of Intent With Melior Pharmaceuticals Ii To Acquire A New Class Of Drug For Parkinson’S Disease
07/06/2021 14:10
June 7 (Reuters) - Adhera Therapeutics Inc ATRX.PK :
* ADHERA THERAPEUTICS SIGNS LETTER OF INTENT WITH MELIOR
PHARMACEUTICALS II TO ACQUIRE A NEW CLASS OF DRUG FOR
PARKINSON’S DISEASE
Source text for Eikon: ID:nGNX5k31Jx
Further company coverage: ATRX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adhera Therapeutics
See all newsBrief: Adhera Therapeutics Says Melior Pharmaceuticals II Terminates License Deal With Respect To MLR-1019
Brief: Adhera Therapeutics Announces CEO, Senior Management Changes, Plans For Nasdaq Uplist
Brief: Adhera Therapeutics Signs Letter Of Intent With Melior Pharmaceuticals Ii To Acquire A New Class Of Drug For Parkinson’S Disease
Ontario to begin offering second doses of COVID-19 vaccines
Brief: Adhera Therapeutics Inc Determined That Co Would Terminate Its Current Business Operations